Dow Jones 30 Stocks SEC Filings — March 16, 2026

16-03-2026

SAIC reported Q4 FY26 revenues of $1.75B, down 5% YoY from $1.838B, and full FY26 revenues of $7.26B, down 3% YoY from $7.479B, primarily due to contract completions, volume ramp-downs, and government shutdown impacts. While adjusted EBITDA margins improved to 10.3% in Q4 (up 70bps) and 9.7% for FY26 (up 20bps), supported by lower SG&A and other recoveries, Q4 net bookings were weak at $0.6B with a 0.3 book-to-bill ratio. FY27 guidance anticipates revenues of $7.0-7.2B with organic growth of -4% to -2%, adjusted EBITDA of $705-715M, and adjusted diluted EPS of $9.50-9.70.

• ·Q4 net bookings $0.6B with book-to-bill 0.3; FY net bookings $7.8B with book-to-bill 1.1.
• ·FY26 share repurchases $422M (4.0M shares); Q4 repurchases $97M.
• ·Quarterly dividend $0.37/share payable April 24, 2026 to record April 10, 2026.
• ·Notable Q4 awards: $629M from Space and Intelligence Community; $95M GAO TIS contract (5-year).
• ·Post-period awards: $330M Space/IC recompete (7-year); $200M Federal Civilian recompete (5-year).
• ·Weighted-average diluted shares: Q4 45.4M (down from 49.0M); FY 46.5M (down from 50.5M).

16-03-2026

Interactive Strength Inc. (TRNR) completed its acquisition of Ergatta, Inc. on March 11, 2026, through a merger making Ergatta a wholly owned subsidiary, with total consideration including $3.5M cash ($1.75M paid upfront, subject to adjustments, and $1.75M deferred via a senior secured promissory note maturing April 30, 2027) and Series D1 Convertible Preferred Stock valued between $5.25M and $9.5M. Equity incentives to Ergatta's senior management included Series D2 Preferred Stock (up to $2M) and Series D3 Preferred Stock (up to $1M). Ergatta stockholders may receive additional milestone-based earnouts; required financial statements and pro forma information will be filed by amendment no later than May 27, 2026.

• ·Merger Agreement originally dated February 18, 2026.
• ·Series D Preferred Stock issued exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
• ·Financial statements and pro forma information for Ergatta to be filed by amendment no later than May 27, 2026 (71 days after original due date).

16-03-2026

The Arena Group reported FY 2025 revenue of $134.8M, up 7% YoY from $125.9M, with gross margin expanding to 50.7% from 44.2% and Adjusted EBITDA rising to $51.5M (38.2% margin) from $27.0M (21.4%), driven by non-advertising revenue growth including $11.6M in publisher revenue and $8.7M in performance marketing; net income reached $124.9M including $96.3M from discontinued operations, versus a $100.7M loss in 2024. However, Q4 2025 revenue declined 22% YoY to $28.2M from $36.2M, gross margin fell to 43.6% from 52.8%, net income dropped to $5.3M from $6.9M, and Adjusted EBITDA decreased to $10.1M from $13.0M despite a stable 35.8% margin. The company reduced debt by $23.5M over FY 2025 (leverage to 1.89x from 4.5x) and grew cash to $10.3M from $4.4M.

• ·Income from continuing operations FY 2025: $28.6M vs loss of $7.7M in 2024.
• ·Accounts receivable net: $22.3M (2025) vs $31.1M (2024).
• ·Term debt: $97.6M (2025) vs $110.4M (2024).
• ·Total liabilities: $117.4M (2025) vs $246.5M (2024), aided by discontinued ops removal.
• ·Stockholders’ deficiency improved to $(4.8M) from $(130.3M).

16-03-2026

Perspective Therapeutics reported full year 2025 results with grant revenue declining to $0.9M from $1.5M in 2024, R&D expenses surging 102% to $84.2M (including $10M impairment), and net loss widening to $103.1M ($1.40/share) from $79.3M ($1.23/share), reflecting heavy clinical investments. Cash decreased to $145M as of December 31, 2025 from $227M prior year but was strengthened by $164M net proceeds from a February 2026 equity offering, funding operations into late 2027. Lead program VMT-α-NET showed favorable safety in 56 patients with no DLTs and 76% progression-free survival in 25 patients, while VMT01 and PSV359 advanced with initial dosing completed.

• ·VMT-α-NET: No DLTs, treatment-related discontinuations, serious renal complications, dysphagia, or clinically significant myelosuppression in 56 patients; 5 serious AEs, none drug-related.
• ·VMT-α-NET Cohort 3 cleared by SMC after 8 patients; additional 8 treated by Feb 28, 2026.
• ·Cohort 2 of VMT-α-NET on track for ~48 weeks follow-up by mid-2026.
• ·VMT01 cohorts at 3.0 mCi (mono/combo with nivolumab) closed for enrollment.
• ·PSV359: Activation for additional sites underway.
• ·Preclinical: One early-stage asset deprioritized in Q4 2025; others ongoing.

16-03-2026

RedCloud Holdings plc (RCT) filed an F-1 registration statement on March 16, 2026, for an initial public offering, providing financial data through June 30, 2025 (H1 FY25), including balance sheet items like common stock, additional paid-in capital, merger reserve, retained earnings, and capitalized software development. The filing discloses operations across geographies such as Nigeria (NG), Argentina (AR), UK (GB), with details on unsecured shareholder term loans, convertible loan agreements (including Tranches One and Two from 2024), and related party transactions; no numerical values are specified in the provided excerpt, limiting period-over-period analysis. It highlights a merger involving RedCloud Technologies Limited and ongoing debt facilities, positioning the company for public listing.

• ·Geographical operations include Nigeria (NG), Argentina (AR), UK (GB), South Africa (ZA), Portugal (PT), and other foreign entities.
• ·Accounts receivable aging categories detailed for periods ending 2025-06-30, 2024-12-31, and 2023-12-31.
• ·Fixed assets include computer equipment and office equipment with depreciation periods.
• ·Convertible loans include Tranche One (drawn Feb 8, 2024) and Tranche Two (Mar 26, 2024).
• ·Unsecured shareholder term loans with multiple drawdowns through 2025-01-31.
• ·Management consultancy agreement with Justin Floyd ongoing from 2019.

16-03-2026

ServisFirst Bancshares, Inc. announced on March 16, 2026, that its Board of Directors declared a quarterly cash dividend of $0.38 per share. The dividend is payable on April 13, 2026, to stockholders of record as of April 1, 2026.

• ·Filing includes Exhibit 99.1: Press Release dated March 16, 2026.

16-03-2026

Fortune Brands Innovations, Inc. announced significant leadership transitions, including Amit Banati stepping aside from the planned CEO role and the Board, David Barry appointed as Interim CEO effective immediately, and Nicholas Fink's accelerated departure. The Board launched a comprehensive CEO search with executive search firm assistance and appointed Ed Garden of Garden Investments as a new director amid a cooperation agreement. CFO Jonathan Baksht stepped down immediately, with Ashley George appointed Interim CFO, while the company plans a proxy proposal to declassify the Board; no financial outlook changes were specified beyond a planned Q1 update.

• ·Changes effective immediately with no disagreements on operations, finances, or practices.
• ·Advisors include Goldman Sachs & Co. LLC, Jefferies LLC, Consello (financial); Wachtell, Lipton, Rosen & Katz (legal); Collected Strategies (communications); LDG Advisory (strategic).
• ·Full-year 2026 outlook update anticipated on Q1 earnings call.
• ·Cooperation Agreement to be filed separately on Form 8-K.

16-03-2026

On March 13, 2026, the Board of Victory Capital Holdings, Inc. approved a one-time grant of performance-based restricted stock awards (Performance Shares) to five key executives under the 2018 Equity Plan, totaling approximately $79.4M in grant value based on the March 13 closing stock price. The awards vest in 25% tranches upon achieving stock price hurdles of $100.01 (50% appreciation), $110.01 (65%), $120.01 (80%), and $133.34 (100%) over a seven-year measurement period starting March 15, 2026, with a one-year post-vesting hold requirement. This grant aims to align executive interests with stockholders, promote retention, and reduce future time-vested grants starting 2026.

• ·Measurement period: seven years commencing March 15, 2026; hurdles achieved if average closing price meets target for five consecutive trading days.
• ·Performance Shares forfeit if hurdles not met by end of measurement period.
• ·No acceleration or continued vesting upon termination except for David C. Brown per employment agreement.
• ·Future annual time-vested grants to recipients expected to decrease starting 2026.

16-03-2026

Marathon Petroleum Corporation filed Definitive Additional Proxy Materials (DEFA14A) on March 16, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No specific proposals, financial data, or voting matters are detailed in the provided header.

• ·Filing Type: DEFA14A (Definitive Additional Materials)
• ·Soliciting Material under §240.14a-12

16-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 16, 2026, announcing via attached press release (Exhibit 99.1) the cancellation of a previously proposed increase in authorized shares following a reverse stock split. The disclosure is furnished under Item 8.01 and not deemed 'filed' for liability purposes. The report was signed by CEO Steven Reinharz.

16-03-2026

Kennedy-Wilson Holdings, Inc. amended its Merger Agreement on March 15, 2026, with Kona Bidco, LLC and Kona Merger Sub, originally dated February 16, 2026, to require a two-thirds affirmative vote of the Company's common stock, Series A, B, and C preferred stock (on specified bases), excluding shares owned by William J. McMorrow, Matthew Windisch, In Ku Lee, and certain Fairfax Financial affiliates to comply with DGCL Section 203. This DEFA14A filing serves as soliciting material for the shareholder vote on the merger. The amendment highlights potential risks including failure to obtain approval, termination fees, operational disruptions, and stock price decline if the deal fails.

• ·Merger requires approval excluding Company Voting Stock 'owned' by specified persons and their affiliates/associates per DGCL Section 203.
• ·2025 annual meeting proxy filed April 25, 2025, contains director/executive info.

16-03-2026

Universal Corporation filed an 8-K/A amendment to disclose compensation details for Steven S. Diel, elected as Senior Vice President and Chief Financial Officer effective April 1, 2026. His package includes an annual base salary of $490,000, target bonus of $350,000, long-term incentive equity awards targeted at $560,000, and a one-time grant of restricted stock units (RSUs) valued at approximately $1.2 million under the 2023 Stock Incentive Plan. The RSUs vest one-third annually on April 1, 2027, 2028, and 2029, subject to continued employment.

• ·Compensation approved by Compensation Committee on March 10, 2026
• ·Initial 8-K filed on February 9, 2026 regarding election on February 3, 2026
• ·RSUs earn dividend equivalent units during vesting periods

16-03-2026

KORU Medical Systems, Inc. announced the retirement of CEO Linda Tharby effective June 30, 2026, with Adam Kalbermatten appointed as President effective March 15, 2026, and succeeding as CEO on July 1, 2026. Tharby will serve as a non-executive advisor and Board member through December 31, 2026, receiving continued base salary at 50% rate during the advisory period and specific equity vesting, while some PSUs were previously cancelled. Kalbermatten's compensation includes base salary increasing to $525,000 and significant LTI awards totaling up to $1.25M annually.

• ·Tharby ineligible for bonus/incentives post-June 30, 2026; remaining unvested awards forfeited after Dec 31, 2026 except specified tranches.
• ·Kalbermatten eligible for severance including 12 months salary continuation and 100% bonus target upon qualifying termination.
• ·Tharby non-compete and restrictive covenants remain in effect; no equity sales during advisory period without Board approval.

16-03-2026

Silvercrest Asset Management Group Inc. (SAMG) issued a press release on March 13, 2026, announcing a teleconference on March 17, 2026, at 8:30 am Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The press release is furnished as Exhibit 99.1 and not deemed filed under securities laws.

• ·Filing submitted on March 16, 2026, covering Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).

16-03-2026

PCB Bancorp reported net income of $37.5M for the year ended December 31, 2025, up 45% YoY from $25.8M in 2024, with net interest income increasing 17% to $104M and total assets growing 7% to $3.28B alongside loans held-for-investment up 7% to $2.82B. Return on average assets improved to 1.15% and efficiency ratio declined to 51.2% from 60.2%. However, nonaccrual loans rose 69% to $7.9M, NPAs increased to 0.24% of assets from 0.15%, provision for credit losses grew 18% to $4.0M, and capital ratios were slightly lower though still well above regulatory thresholds.

• ·Earnings per common share diluted $2.58 for 2025, up from $1.74 in 2024.
• ·Cash dividends declared per common share $0.80 for 2025, up from $0.72.
• ·Dividend payout ratio 30.89% for 2025, improved from 41.14%.
• ·All capital ratios remain well capitalized per PCA thresholds.
• ·ASC 326 adoption increased total ACL on loans by $1.1M to $26.0M.

16-03-2026

LivePerson Inc (LPSN) reported FY 2025 revenue of $243.7M, down 22% YoY from $312.5M amid broad declines. Operating expenses decreased significantly across categories, including cost of revenue -10%, sales and marketing -22%, general and administrative -44%, product development -31%, depreciation and amortization -46%, and goodwill impairment -31%, driven by headcount reductions (e.g., product development headcount down 41% to 239). Restructuring costs edged up 5% YoY to $11.7M.

16-03-2026

Allison Transmission Holdings, Inc. (ALSN) filed an 8-K/A on March 16, 2026, amending its January 2, 2026 original 8-K to provide required financial statements and pro forma information under Item 9.01 for the January 1, 2026 acquisition of Dana Incorporated's off-highway business (Dana Business) for $2.732 billion, financed via cash on hand and debt. The deal stems from a June 11, 2025 Stock Purchase Agreement. No performance metrics or period-over-period comparisons are detailed in the filing itself, with exhibits referencing audited financials for years ended December 31, 2024 and 2023, and unaudited nine-month data as of September 30, 2025.

• ·Stock Purchase Agreement dated June 11, 2025
• ·Audited combined financial statements of Dana Business for years ended December 31, 2024 and December 31, 2023 (Exhibit 99.1)
• ·Unaudited condensed combined financial statements as of September 30, 2025 and for nine months ended September 30, 2025 and 2024 (Exhibit 99.2)
• ·Pro forma condensed combined balance sheet as of September 30, 2025 and statements of operations for nine months ended September 30, 2025 and year ended December 31, 2024 (Exhibit 99.3)

16-03-2026

Sprott Physical Silver Trust (PSLV) filed its Annual Report on Form 40-F dated March 16, 2026, providing an overview of the Trust's structure, investment and operating restrictions, silver sector context, unit descriptions, net asset value calculation methods, market information, redemption processes, governance, fees, distribution policy, tax considerations, and risk factors. The document includes details on valuation procedures for cash, receivables, liabilities, and portfolio transactions, but contains no specific financial performance metrics, period-over-period comparisons, or quantitative data on assets, income, or changes.

16-03-2026

Mountain Crest Acquisition Corp. V reported a widened net loss of $431,161 for the year ended December 31, 2025, up 15% YoY from $374,454 in 2024, driven by sharply lower interest income on the Trust Account ($46,114 vs. $265,306). While general and administrative expenses declined 24% to $471,782 and net cash used in operating activities improved to $742K from $921K, total assets fell to $874K from $1.3M, cash dropped to $12K, and the Trust Account balance decreased 27% to $841K amid ongoing redemptions reducing redeemable shares to 72,123 from 101,104. Stockholders' deficit worsened to $(3.7M) from $(3.4M), with related-party promissory note rising to $1.3M.

• ·Proposal to amend Charter to extend Combination Period to November 16, 2024 with $0.10 per Public Share deposits for three-month extensions.
• ·Deferred underwriting commission obligation of $2.07M upon business combination.
• ·Conversion of $600K related-party promissory note to equity in 2024.
• ·Reversal of $194K excise tax payable in 2025.
• ·Net cash provided by investing activities $363K in 2025 (vs $4.72M in 2024), mainly from $336K redemption withdrawals.

16-03-2026

Vanguard Green Investment Ltd reported zero revenue for both the three and six months ended January 31, 2026, with net losses widening significantly to $30,132 (3M, +125% YoY) and $47,129 (6M, +62% YoY) due to elevated general and administrative expenses. Total assets contracted 66.5% to $5,110 from $15,258 as of July 31, 2025, while cash equivalents dropped to $55 from $93; stockholders' deficit deepened to $(771,707) from $(724,578). Non-current liabilities improved with a 48% reduction to $18,093, but current liabilities rose 7.6% to $758,724, largely from increased director loans.

• ·Prepayments decreased to $5,055 from $15,165 as of Jul 31, 2025.
• ·Loan from director increased to $484,543 from $445,001.
• ·Amount due to related parties remained flat at $96,513.
• ·G&A expenses for six months rose to $43,495 from $23,698 YoY.

16-03-2026

Innovative Industrial Properties, Inc. (IIPR) executed full-building leases for two properties totaling 122,000 square feet in Illinois and California. However, it settled lawsuits with PharmaCann over rent defaults on three properties in New York, Ohio, and Pennsylvania, with tenant surrender expected by May 20-26, 2026, and entered defaults on March 2026 rents from Cannabist ($0.6M, 2.7% of 2025 rental revenues) and Battle Green ($0.8M, 2.9% of 2025 rental revenues), planning to use security deposits to cover. Cannabist's 20 leases represent 6.3% of 2025 total rental revenues, though 19 remain current.

• ·PharmaCann settlement includes monetary judgments reducible by escrowed rent funds; consents executed March 13, 2026.
• ·Cannabist sold Virginia operations to Millstreet affiliate in February 2026, reducing IIPR properties leased to Cannabist from 21 to 20.
• ·Cannabist current on 19 of 20 leases excluding the defaulted Pennsylvania property.
• ·IIPR intends to aggressively enforce rights under defaulted Cannabist and Battle Green leases, potentially including eviction.

16-03-2026

Prosperity Bancshares, Inc. issued its DEF 14A proxy statement dated March 16, 2026, for the 2026 Annual Meeting on April 21, 2026, to elect four Class I directors to serve until the 2029 annual meeting, ratify Deloitte & Touche LLP as independent auditors for the year ending December 31, 2026, and hold an advisory 'Say-On-Pay' vote on named executive officer compensation. The record date is March 2, 2026, with 101,489,022 shares of common stock outstanding. The proxy includes sections on director nominees, corporate governance, director and executive compensation, pay versus performance, and audit committee matters.

• ·Annual Meeting location: East Lawn Board Room of Prosperity Bank, 80 Sugar Creek Center Boulevard, Sugar Land, Texas 77478, at 10:00 a.m. local time.
• ·Proxy materials and Form 10-K for fiscal year ended December 31, 2025 available at https://www.proxydocs.com/PB.

16-03-2026

Norwegian Cruise Line Holdings Ltd. announced that its board has set June 11, 2026, as the date for the 2026 Annual General Meeting of Shareholders, with the record date of close of business on April 15, 2026. Non-Rule 14a-8 shareholder proposals and director nominations must be submitted by close of business on March 26, 2026, to the company's secretary in Miami, Florida. Deadlines for Rule 14a-8 proposals and Rule 14a-19 proxy solicitations remain unchanged from the 2025 Proxy Statement.

• ·Meeting details, including time and location, to be provided in the proxy statement for the 2026 Annual Meeting.
• ·Proposals must comply with SEC rules and the Company's Bye-laws.
• ·Company address for submissions: 7665 Corporate Center Drive, Miami, Florida 33126.

16-03-2026

Zevra Therapeutics sold its entire serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, to Commave Therapeutics for $50 million, simultaneously resolving a 2024 lawsuit in Delaware Chancery Court. The company fully repaid its $63 million term loan prior to the agreement, achieving a debt-free balance sheet and enhanced financial flexibility. This allows Zevra to focus on its rare disease pipeline, including therapies for Niemann-Pick disease type C (NPC).

• ·2019 license agreement granted Commave exclusive license to certain SDX products.
• ·Litigation initiated by Commave against Zevra in Delaware Chancery Court in 2024.
• ·Annual Report on Form 10-K for year ended December 31, 2025, filed March 9, 2026.

16-03-2026

Flowserve Corporation (NYSE: FLS) elected Brian Savoy to its Board of Directors effective March 16, 2026, appointing him to the Audit Committee and Technology, Innovation and Risk Committee. Savoy, current CFO and Executive Vice President at Duke Energy, brings extensive power industry leadership, including nuclear expertise, to support Flowserve's growth in power markets and the Flowserve Business System. Company leadership expressed enthusiasm for his financial, transformation, and strategy experience.

• ·Brian Savoy serves as board member and audit committee chair for the Electric Power Research Institute.
• ·Brian Savoy holds a Bachelor of Business Administration in accounting from Lamar University and is a certified public accountant.

16-03-2026

Associated Banc-Corp filed Definitive Additional Materials (DEFA14A) on March 16, 2026, as part of its proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee required and is not preliminary or confidential. No financial metrics, changes, or substantive proxy details are disclosed in the provided notice.

• ·Filed by the Registrant
• ·No fee required

16-03-2026

Baxter International Inc. announced the departure of EVP and CFO Joel Grade to prioritize family matters, with him continuing in an advisory role until April 30, 2026. Anita Zielinski, who joined in 2025 as SVP, Chief Accounting Officer and Controller, has been appointed interim CFO effective immediately while the company searches for a permanent replacement. Baxter is reiterating its full-year 2026 financial outlook originally provided on February 12, 2026, signaling continuity amid the transition.

• ·Anita Zielinski previously served as SVP and CFO, U.S. Foodservice Operations at Sysco Corporation and spent over 20 years at Ernst & Young LLP as an audit partner.
• ·Media Contact: Stacey Eisen, (224) 948-5353; Investor Contact: Kevin Moran, (224) 948-3085

16-03-2026

Orange County Bancorp, Inc. reported net income of $41.6 million for the year ended December 31, 2025, a 49.2% YoY increase from $27.9 million, fueled by net interest income growth of 13.4% to $104.1 million and noninterest income surge of 44.9% to $23.1 million. Average total assets expanded to $2.59 billion from $2.48 billion, with net interest margin improving to 4.18% from 3.83%. However, non-performing loans rose sharply to $11.1 million from $6.3 million, lifting the NPL to total loans ratio to 0.57% from 0.35%, and noninterest expenses increased 4.1% to $67.9 million.

• ·Banking segment net income $37.5M in 2025 vs $25.4M in 2024; Wealth Management $4.1M vs $2.5M.
• ·Provision for credit losses $7.7M in 2025, down 19.4% from $9.6M.
• ·Non-accrual commercial real estate loans $8.7M at Dec 31 2025 vs $6.0M at Dec 31 2024.
• ·Investment securities gains (losses) -$0.6M in 2025.
• ·Proceeds from bank owned life insurance $3.6M in 2025 (new).
• ·Total assets at Dec 31 2025 $2.66B vs $2.51B at Dec 31 2024.

16-03-2026

Babcock & Wilcox Enterprises, Inc. filed an 8-K on March 16, 2026, disclosing under Item 7.01 that it posted an investor presentation on its website (www.babcock.com). The presentation is attached as Exhibit 99.1 and incorporated by reference, but is not deemed 'filed' under securities laws. The filing was signed by Cameron Frymyer, Executive Vice President and Chief Financial Officer.

• ·Commission File Number: 001-36876
• ·IRS Employer Identification No.: 47-2783641
• ·Principal Executive Offices: 1200 East Market Street, Suite 650, Akron, Ohio 44305
• ·Telephone: (330) 753-4511

16-03-2026

Embassy Bancorp, Inc. reported total assets of $1.80B as of Dec 31, 2025, up 5.6% YoY from $1.70B, driven by loan growth to $1.28B net (up 1.8%) and deposits to $1.64B (up 5.6%), with net interest income rising 17.2% YoY to $42.4M and net interest margin expanding to 2.52% from 2.26%. Stockholders' equity increased 19.9% to $127.6M, supported by retained earnings growth and reduced accumulated other comprehensive loss. However, nonperforming loans remained flat at 0.04% of total loans, and certain yields like interest-bearing deposits declined to 4.28% from 5.32%.

• ·Average taxable loans: $1.25B in 2025 (up from $1.24B), interest $57.3M (up 7.3%).
• ·Securities available for sale: $342M at Dec 31, 2025 (up from $281M).
• ·Allowance for credit losses: $12.0M at Dec 31, 2025 (down slightly from $12.2M).
• ·Net charge-offs to average loans: 0.01% in 2025 (vs -0.02% recovery in 2024).

16-03-2026

On March 11, 2026, the Board of Directors of BILL Holdings, Inc. appointed Rohini Jain, the company's Chief Financial Officer, to also serve as principal accounting officer under the Securities Exchange Act of 1934. No additional compensation will be provided for this role. Biographical information on Ms. Jain is incorporated from the company's Form 8-K filed on June 2, 2025.

• ·Principal executive offices: 6220 America Center Drive, Suite 100, San Jose, California 95002
• ·Common Stock ($0.00001 par value) trades as BILL on NYSE

16-03-2026

Eve Holding, Inc. filed an 8-K on March 16, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), likely disclosing preliminary or non-GAAP financial measures with attached exhibits. A 10-K annual report was also filed the same day. No specific financial metrics, improvements, or declines are detailed in the provided filing metadata.

• ·Company address: 1400 General Aviation Drive, Melbourne, FL 32935
• ·CIK: 0001823652
• ·SIC: 3721 (Aircraft)
• ·Fiscal year end: December 31

16-03-2026

Gevo, Inc. disclosed that Dr. Angelo Amorelli informed the Board on March 11, 2026, that he will not stand for re-election at the 2026 Annual Meeting of Stockholders for personal reasons, with no disagreements on operations, policies, or practices. He will continue serving until the expiration of his term at the Annual Meeting. The company expressed thanks for his contributions.

• ·Filing date: March 16, 2026
• ·Date of earliest event: March 11, 2026

16-03-2026

NATURAL GAS SERVICES GROUP INC (NGS) reported FY2025 total revenues of $172.3M, up 10% YoY from $156.7M, primarily driven by rental revenues surging 13.9% to $164.3M with rented horsepower up 14.4% to 562,676 and utilization improving to 84.9%. Adjusted EBITDA increased 16% to $81.0M and net income rose to $19.9M from $17.2M. However, sales revenues plummeted 47.6% to $4.0M with negative adjusted gross margin of -$0.2M, and aftermarket services declined 18.3% to $4.0M despite margin improvement.

• ·Fleet horsepower available at period end increased to 662,542 in 2025 from 598,840 in 2024 (+10.6%).
• ·Unit utilization at period end rose slightly to 65.0% from 63.2% (+1.8%).
• ·Impairments increased to $2.6M in 2025 from $0.8M in 2024.
• ·SG&A expenses as % of revenues improved slightly to 13.0% from 13.4%.
• ·Depreciation and amortization rose 16.9% to $36.7M.

16-03-2026

Liberty Broadband Corporation's board of directors declared a quarterly cash dividend on its Series A Cumulative Redeemable Preferred Stock, payable on April 15, 2026, to stockholders of record as of March 31, 2026. The announcement was issued via press release on March 12, 2026, under Regulation FD disclosure. No other financial metrics or performance comparisons were provided.

• ·SEC filing dated March 16, 2026, for event on March 12, 2026
• ·Company headquartered at 12300 Liberty Blvd., Englewood, Colorado 80112

16-03-2026

Warner Bros. Discovery, Inc. (WBD) has filed a preliminary proxy statement (PREM14A) soliciting shareholder approval for a proposed merger with Paramount Skydance Corporation (PSKY), whereby PSKY's wholly-owned subsidiary, Prince Sub Inc., will merge with WBD, resulting in WBD becoming a wholly-owned subsidiary of PSKY. WBD directors and executive officers have interests in the merger that differ from general shareholders, which the board considered in its recommendation. Appraisal rights are available under Section 262 of the DGCL, but numerous risks are disclosed, including potential failure to obtain approvals, litigation, and business disruptions.

• ·Filing date: March 16, 2026
• ·References Annual Report on Form 10-K for fiscal year ended December 31, 2025
• ·Appraisal rights require compliance with Section 262 of the DGCL, including written demand before vote and holding shares through Effective Time
• ·WBD Common Stock trades on Nasdaq under symbol 'WBD'; PSKY Class B Common Stock under 'PSKY'
• ·Innisfree M&A Incorporated as proxy solicitor: (877) 750-8338 for stockholders

16-03-2026

Vine Hill Capital Investment Corp., a SPAC, has entered a Business Combination Agreement dated September 8, 2025, to merge with a subsidiary of Odysseus Holdings Limited (to be renamed CoinShares PLC) and acquire CoinShares International Limited via a $1.2B equity valuation scheme of arrangement, with a $50M PIPE investment from an institutional investor for 6,666,667 shares total. Pro forma ownership post-merger shows CoinShares shareholders holding 78.4% in no-redemption scenario but up to 91.5% in maximum redemption; however, Vine Hill public shareholders' stake dilutes from 14.3% to 0% across scenarios, with potential trust outflows up to $231.5M at $10.52/share.

• ·PIPE Investor may reduce PIPE obligation by acquiring non-redeemed Vine Hill shares (currently holds 1,967,329 shares representing 39.3% of 5M commitment).
• ·Holdco applying for Nasdaq listing of ordinary shares under 'CS' and warrants under TBD symbol; listing approval a closing condition.
• ·Vine Hill net tangible assets redemption limit: cannot fall below $5,000,001.
• ·CoinShares Options: Vested convert to cash; unvested to Holdco options adjusted by Equity Exchange Ratio ($1.2B / Fully Diluted Equity Securities / $10.00).

16-03-2026

Everest Group, Ltd. entered into a Separation, Transition Services and General Release Agreement dated March 13, 2026, with its former Executive Vice President and General Counsel, Ricardo Anzaldua, in connection with a previously announced General Counsel transition. The Company agreed to pay $7.25 million in recognition of his service, accrued payments, and for providing advisory services during an extended transition period of up to nine months. The agreement also includes a waiver of Mr. Anzaldua's non-compete covenant after advisory services end and an extension of his non-solicit covenant for an additional six months.

• ·Agreement filed in connection with previously announced General Counsel transition.
• ·Forfeiture of previously granted equity awards by Mr. Anzaldua.
• ·Full release of all contractual entitlements, claims, rights, and other undertakings.
• ·Full text of the Agreement to be filed as an exhibit to a subsequent Form 10-Q.

16-03-2026

IPG Photonics Corporation announced via press release that the Local Division of the Unified Patent Court in Dusseldorf, Germany, issued a decision on March 16, 2026, in a previously disclosed patent infringement lawsuit brought by affiliates of Trumpf SE & Co. KG against IPG Laser GmbH & Co. KG, the Company's German subsidiary. The press release is attached as Exhibit 99.1. No financial impact or specific details on the decision outcome were disclosed in the filing.

16-03-2026

Rafael Holdings reported a Q2 FY2026 net loss of $6.4M ($0.13/share), wider than $4.6M ($0.19/share) YoY due to sharply higher R&D expenses of $4.5M from Cyclo Therapeutics consolidation, though G&A fell to $2.3M and revenue rose to $211k. For the first half FY2026, net loss widened to $16.2M from $13.6M YoY with R&D at $12.0M versus flat G&A of $5.1M and revenue up to $451k; cash was $37.8M, down from $52.8M at FY2025 end. Positive progress noted on the Phase 3 TransportNPC™ study for Trappsol® Cyclo™, with top-line results expected in Q3 2026.

• ·Cyclo Therapeutics acquired in March 2025, leading to consolidation of its expenses.
• ·Data Monitoring Committee recommended continuing Phase 3 trial after 48-week review.
• ·Total current assets $42.4M as of Jan 31, 2026 vs $56.7M as of Jul 31, 2025.

16-03-2026

Strive, Inc. filed Definitive Additional Proxy Materials (DEFA14A) on March 16, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as soliciting material under Rule 240.14a-12. No specific proposals, financial data, or other substantive content is detailed in the provided header.

16-03-2026

Comtech reported Q2 FY26 net sales of $106.8 million, down 15.6% YoY from $126.6 million, primarily due to strategic elimination of low-margin products and U.S. government shutdown impacts, with S&S segment sales declining 31.3% to $50.6 million. However, gross profit rose to $36.2 million (33.9% margin vs. 26.7% prior), Adjusted EBITDA increased 214% to $9.1 million, operating loss narrowed to $1.2 million from $10.3 million, net bookings surged 120.9% to $175.4 million (1.64x book-to-bill), and backlog reached $731.6 million. Allerium segment sales grew 6.2% YoY to $56.2 million, while the company generated $4.9 million in operating cash flow and ended with $49.9 million liquidity.

• ·S&S book-to-bill ratio improved slightly to 0.68x from 0.64x YoY.
• ·Allerium book-to-bill ratio 2.51x vs. 0.61x YoY.
• ·Backlog decreased to $731.6M from $763.8M YoY but up from $672.1M prior quarter.
• ·Ongoing litigation with former CEO Ken Peterman via American Arbitration Association.

16-03-2026

Permianville Royalty Trust announced a monthly cash distribution of $0.010 per unit, payable April 14, 2026 to unitholders of record March 31, 2026, based on December 2025 oil and November 2025 natural gas production. Natural gas cash receipts surged $2.4 million to $3.4 million due to prior period adjustments and timing, but oil cash receipts fell $0.2 million to $1.7 million amid delays from operatorship transfers. Operating expenses rose $0.6 million to $3.0 million while capital expenditures declined $0.2 million to $0.6 million, and the Sponsor withheld an additional $0.6 million for a development reserve now at $0.9 million.

• ·Oil production: 29,538 Bbls (953 Bbls/D) at $55.90/Bbl current month vs 32,171 Bbls (1,072 Bbls/D) at $57.95/Bbl prior month
• ·Natural gas production: 1,133,064 Mcf (37,769 Mcf/D) at $2.97/Mcf current month vs 314,444 Mcf (10,143 Mcf/D) at $2.96/Mcf prior month
• ·Net profits interest: 80% from predominantly non-operated properties in Texas, Louisiana, and New Mexico

16-03-2026

Veracyte, Inc. (VCYT) announced the appointment of Dr. Kevin Haas as Chief Development and Technology Officer, effective March 24, 2026, following board approval on March 13, 2026. Dr. Haas, formerly Chief Technology Officer at Myriad Genetics, Inc. (MYGN) since February 2021, brings extensive experience in genetic testing and bioinformatics. Compensation includes an initial annual base salary of $500,000, target bonus opportunity of 55% of eligible earnings (prorated for 2026), and equity awards with $3M total target value vesting over four years.

• ·Appointment announced March 16, 2026; offer letter dated March 13, 2026.
• ·Dr. Haas previously held roles as SVP Technology, SVP Engineering, VP and Senior Director of Bioinformatics at Myriad.
• ·Equity awards under 2023 Equity Incentive Plan; standard indemnification agreement to be executed.
• ·No family relationships, arrangements, or material transactions under Item 404(a) of Regulation S-K.

16-03-2026

Universal Logistics Holdings, Inc. (ULH) reported 2025 operating revenues of $1.56B, down 15.6% YoY from $1.85B in 2024, swinging to a net loss of $99.9M (-6.4% margin) from $129.9M profit (7.0% margin), driven by a $124M impairment expense and a $162M operating loss in Intermodal (vs -$28M prior). While Value-Added services rose to 45.7% of revenues (from 42.6%) and Dedicated services to 21.7% (from 18.6%), Brokerage services plunged to 4.7% (from 9.8%) and Intermodal revenues fell to $257M (from $309M). In 2024, revenues had grown 11.1% YoY from $1.66B with net income up 39.8% to $129.9M.

• ·2025 EPS basic and diluted: -$3.79 (vs $4.94 in 2024)
• ·Dividends per share flat at $0.42 across 2023-2025
• ·Goodwill declined to $106M in 2025 from $207M in 2024
• ·Total stockholders' equity down to $540M from $647M
• ·Intermodal revenues down 16.7% YoY to $252M in detailed service breakdown

16-03-2026

Honeywell Aerospace Inc. entered into a Registration Rights Agreement dated March 16, 2026, with representatives Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC, covering $16B aggregate principal amount of Senior Notes issued pursuant to a Purchase Agreement dated March 10, 2026. This includes $10B in new money notes (various tranches maturing 2028-2036) issued by the Company and $6B in exchange notes (maturing 2046-2066) sold by selling securityholders, all guaranteed by Honeywell International Inc. The agreement mandates a Registered Exchange Offer to be completed no later than 365 days after the Honeywell Aerospace Spin-Off or related successor assumption.

• ·Registered Exchange Offer must be completed no later than 60 days after Exchange Offer Registration Statement effectiveness, but no later than 365 days after Honeywell Aerospace Spin-Off consummation or successor assumption under Indenture Article 10.
• ·Exchange Offer open for not less than 20 Business Days.
• ·Securities issued under Base Indenture and First Supplemental Indenture, both dated March 16, 2026.